Key result
Early empagliflozin after AMI showed a non-significant association with lower 6-month major cardiovascular events, while L2 logistic regression predicted major cardiovascular events with an AUC of 0.673.
Why the study?
Although SGLT2 inhibitors are increasingly prescribed after AMI, residual risk on this therapy is rarely examined alongside its association with outcomes within the same cohort.
Does early empagliflozin therapy reduce six-month major adverse cardiovascular events in patients with acute myocardial infarction treated by primary percutaneous coronary intervention, and can machine learning models accurately stratify residual MACE risk in this population?
Cohort (n=311)
Open-label
No
Does early empagliflozin therapy reduce six-month major adverse cardiovascular events in patients with acute myocardial infarction treated by primary percutaneous coronary intervention, and can machine learning models accurately stratify residual MACE risk in this population?
In post-AMI patients treated with primary PCI, classical L2-regularized logistic regression matched complex machine learning algorithms in achieving moderate discrimination for 6-month MACE, while early empagliflozin showed a small, non-significant hypothesis-generating association with fewer events after propensity matching.
Answers are grounded in this paper and cite their sources.
Non-significant MACE association with early empagliflozin should not change practice; leaves open efficacy for randomized post-AMI trials.
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are increasingly prescribed after acute myocardial infarction (AMI), yet residual risk on this therapy is rarely examined alongside the drug’s association with outcomes in one cohort. We investigated 311 patients with AMI at one center (January 2024–May 2025): 251 received early empagliflozin 10 mg/day with standard therapy and were followed prospectively for six months; 60 contemporaneous patients without an SGLT2 inhibitor formed a non-randomized control group. The endpoint was six-month major adverse cardiovascular events (MACEs): all-cause death, non-fatal reinfarction, urgent percutaneous coronary intervention, or unplanned cardiovascular hospitalization. Classical and machine learning classifiers were compared under repeated nested cross-validation, with imputation, scaling, and tuning inside each fold; the empagliflozin–MACE association was estimated by propensity-score matching on 20 covariates. MACE occurred in 83 patients (26.7%; 24.7% with empagliflozin vs. 35.0% in controls), including 17 deaths (5.5%). Cross-validated backward elimination reduced 24 candidate predictors to eight: body mass index, prior infarction, current smoking, mineralocorticoid-receptor antagonist use, peak A velocity, left-ventricular end-diastolic volume, empagliflozin exposure, and discretized total cholesterol. On these features, L2-regularized logistic regression reached a pooled out-of-fold area under the curve of 0.673 (95% confidence interval 0.601–0.741) with good calibration (slope 0.88), matching random forest, gradient boosting, XGBoost, support-vector machine, k-nearest neighbors, and a multilayer perceptron. After matching (44 pairs), the odds ratio for MACE with empagliflozin was 0.79 (95% CI 0.32–1.98). Discrimination was moderate and needs external validation; the association between empagliflozin and fewer events was small and hypothesis-generating.
No takes yet. Share an insight, caveat, or question.
Хусаиновна et al. (2026) conducted a cohort in Acute myocardial infarction (n=311). Early empagliflozin therapy vs. Standard therapy without an SGLT2 inhibitor was evaluated on 6-month major adverse cardiovascular events (all-cause death, non-fatal reinfarction, urgent PCI, or unplanned cardiovascular hospitalization) (OR 0.61, 95% CI 0.33-1.11, p=0.108). Early empagliflozin after AMI showed a non-significant association with lower 6-month major cardiovascular events, while L2 logistic regression predicted major cardiovascular events with an AUC of 0.673.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: